Advertisement

Antiproliferative Evaluation of (E)-3-(3-(Allyloxy)-2-Methoxyphenyl)-1-(2,4,6-Trimethoxyphenyl)Prop-2-En-1-One as a Novel Apoptosis Inducer Against Prostate Cancer PC-3 Cells

  • Dong-Jun Fu
  • Ping Li
  • Yi-Rui Kuang
  • Li-Le Jiang
  • Ming-Chao Zhu
  • Si-Chen Li
  • Guo Zheng
  • Rui Zhang
  • Sai-Yang ZhangEmail author
  • Jiang-Feng LiEmail author
Article
  • 2 Downloads

(E)-3-(3-(Allyloxy)-2-methoxyphenyl)-1-(2,4,6-trimethoxyphenyl)prop-2-en-1-one displayed potent antiproliferative activity against the PC-3 cell line. For colony assay, it can inhibit the colony formation at a concentration of 10 μM. Morphological changes of PC-3 cells were determined using DAPI (4′,6-diamidino-2-phenylindole) staining and chromatin condensation. Treatment with this compound at 10 μM induced apoptosis from 2.0% to 30.4% compared with control according to flow cytometry analysis. It also induced the downregulation of apoptosis-related markers Bcl-2 and XIAP (X-linked inhibitor of apoptosis protein). However, treatment with NAC (N-acetyl-L-cysteine) almost completely attenuated chalcone-induced cell inhibition and cell apoptosis in PC-3 cells.

Keywords

PC-3 cells colony formation morphological changes apoptosis Bcl-2 NAC 

Notes

Acknowledgments

This work was supported by the National Natural Sciences Foundations of China (Project Nos. 81703541 and 81673322) and project funded by the China Postdoctoral Science Foundation. This work was also supported by MEDCHEMEXPRESS. Thanks to MCE Award for Scientists Promoting Biology and Medicine Research.

References

  1. 1.
    X. Xu, R. Ge, L. Li, et al., Eur. J. Med. Chem., 143, 1325 – 1344 (2018).CrossRefGoogle Scholar
  2. 2.
    N. N. Yokoyama, S. Shao, B. H. Hoang, et al., Am. J. Clin. Exp. Urol., 2, 27 – 44 (2014).Google Scholar
  3. 3.
    M. Bassetto, S. Ferla, F. Pertusati, et al., Eur. J. Med. Chem., 118, 230 – 243 (2016).CrossRefGoogle Scholar
  4. 4.
    D. J. Fu, J. Song, Y. H. Hou, et al., Eur. J. Med. Chem., 138, 1076 – 1088 (2017).CrossRefGoogle Scholar
  5. 5.
    D. J. Fu, J. F. Liu, R. H. Zhao, et al., Molecules, 22, 1470 (2017).CrossRefGoogle Scholar
  6. 6.
    D. J. Fu, L. Fu, Y. C. Liu, et al., Sci. Rep., 7, 12788 (2017).CrossRefGoogle Scholar
  7. 7.
    D. J. Fu, S. Y. Zhang, Y. C. Liu, et al., Bioorg. Med. Chem. Lett., 26, 3918 (2016).CrossRefGoogle Scholar
  8. 8.
    D. J. Fu, Y. H. Hou, S. Y. Zhang, et al., J. Chem. Sci., 130, 6 (2018).CrossRefGoogle Scholar
  9. 9.
    D. J. Fu, S. Y. Zhang, Y. C. Liu, et al., Med. Chem. Comm., 7, 1664 – 1671 (2016).CrossRefGoogle Scholar
  10. 10.
    M. Xiao, M. Li, and C. S. Reynolds, Biol. Rev., 93, 1399 – 1420 (2018).CrossRefGoogle Scholar
  11. 11.
    D. J. Fu, R. H. Zhao, J. H. Li, et al., Mol. Divers., 21, 1 – 10 (2017).CrossRefGoogle Scholar
  12. 12.
    J. M. Adams and S. Cory, Science., 281, 1322 (1998).CrossRefGoogle Scholar
  13. 13.
    A. Cimmino, G. A. Calin, M. Fabbri, et al., Proc. Natl. Acad. Sci. USA, 102, 13944 (2005).CrossRefGoogle Scholar
  14. 14.
    E. N. Shiozaki, J. Chai, D. J. Rigotti, et al., Mol. Cell, 11, 519 – 527 (2003).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Dong-Jun Fu
    • 1
  • Ping Li
    • 2
  • Yi-Rui Kuang
    • 3
  • Li-Le Jiang
    • 3
  • Ming-Chao Zhu
    • 1
  • Si-Chen Li
    • 2
  • Guo Zheng
    • 2
  • Rui Zhang
    • 2
  • Sai-Yang Zhang
    • 2
    Email author
  • Jiang-Feng Li
    • 2
    Email author
  1. 1.School of Pharmaceutical Sciences and Collaborative Innovation Center of New Drug Research and Safety EvaluationZhengzhou UniversityZhengzhouChina
  2. 2.School of Basic MedicineZhengzhou UniversityZhengzhouChina
  3. 3.The Second Affiliated Hospital of Zhengzhou UniversityZhengzhouChina

Personalised recommendations